Get 10 Free Leads on us
Use our Chrome Extension & instantly connect with prospects
Exelixis
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroi d cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan.
...Read MoreEXELIXIS Inc
Exelixis
Exelixis Ltd
Exelixis US LLC
Exelixis Global Services Inc
Headquarters
$2.1 B
1,310
1994
Exelixis raised a total of $118.3 M in funding over 1 rounds, and is a public traded company.
NASDAQ: EXEL
Here's a list of some of the top trending technologies and APIs used by Exelixis.
(21 Technologies)
(16 Technologies)
(16 Technologies)
(15 Technologies)
(14 Technologies)
Company | Employees | Revenue | Top technologies |
---|---|---|---|
ACADIA | 630 | $2.3 B | |
Ionis Pharmaceuticals | 927 | $813.5 M | |
Blueprint Medicines | 638 | $362.8 M | |
Pharmacyclics | 1,018 | $343.6 M | |
Dendreon | 764 | $255.7 M |